Xue Yuhang, Zhang Yuzhe, Ding Xintao, Wu Xinyu, Li Bo, Zhang Ye, Gao Yongju
Department of Nuclear Medicine, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, China.
Ann Nucl Med. 2025 Jan;39(1):9-20. doi: 10.1007/s12149-024-01998-2. Epub 2024 Nov 5.
The treatment of radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) has made significant advancements in the twenty-first century. This study aimed to assess the current state of research and identify potential new directions by conducting a bibliometric analysis of scientific publications on RAIR-DTC treatment. Publications relevant to RAIR-DTC, published from January 1, 2000, to December 31, 2023, were retrieved from the Web of Science Core Collection. Bibliometric analyses of major keywords, authors, countries, institutions, publications, and journals were conducted using CiteSpace and VOSviewer. A total of 859 papers were included in the analysis. The results demonstrated a rising trend in the number of publications over time. The United States was identified as the leading contributor in terms of publication output, citations, and international collaborations. Gustave Roussy emerged as the top organization in publication productivity, while the journal Thyroid had the highest number of related publications. The research on RAIR treatment was categorized into three key hotspots: clinical trials of targeted therapies, novel therapeutic strategies, and debates surrounding the RAIR-DTC management. RAIR-DTC research is expanding from the clinical trial phase of tyrosine kinase inhibitor monotherapy to a more complex combination therapy strategy, in particular, the synergistic effect of immune checkpoint inhibitors and other therapeutic agents, requiring more high-quality prospective studies to validate the clinical benefits. Moreover, the timely identification of RAIR-DTC patients holds the potential to enable early disease intervention, constituting a pivotal novel research direction in the future.
放射性碘难治性分化型甲状腺癌（RAIR-DTC）的治疗在21世纪取得了重大进展。本研究旨在通过对RAIR-DTC治疗的科学出版物进行文献计量分析，评估当前的研究现状并确定潜在的新方向。从Web of Science核心合集中检索了2000年1月1日至2023年12月31日发表的与RAIR-DTC相关的出版物。使用CiteSpace和VOSviewer对主要关键词、作者、国家、机构、出版物和期刊进行了文献计量分析。共有859篇论文纳入分析。结果表明，出版物数量随时间呈上升趋势。美国在出版物产出、引用次数和国际合作方面被确定为主要贡献者。古斯塔夫·鲁西研究所成为出版物生产力最高的机构，而《甲状腺》杂志的相关出版物数量最多。RAIR治疗的研究分为三个关键热点：靶向治疗的临床试验、新型治疗策略以及围绕RAIR-DTC管理的争论。RAIR-DTC研究正从酪氨酸激酶抑制剂单药治疗的临床试验阶段扩展到更复杂的联合治疗策略，特别是免疫检查点抑制剂和其他治疗药物的协同作用，这需要更多高质量的前瞻性研究来验证临床益处。此外，及时识别RAIR-DTC患者有可能实现疾病的早期干预，这构成了未来一个关键的新研究方向。
